This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Gary E. Meininger: Innovator in Anti-Diabetic Treatments
Introduction
Gary E. Meininger is a notable inventor based in Livingston, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of type II diabetes. His innovative approach focuses on the use of fused aromatic compounds that exhibit anti-diabetic activity.
Latest Patents
Gary E. Meininger holds a patent for a method of treatment using fused aromatic compounds having anti-diabetic activity. This patent describes fused aromatic compounds of Formula I as PPAR gamma agonists or partial agonists. These compounds are useful for weekly dosing in the treatment or control of type II diabetes, including conditions such as hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. He has 1 patent to his name.
Career Highlights
Gary is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His work at Merck has allowed him to further develop his innovative ideas and contribute to advancements in diabetes treatment.
Collaborations
Throughout his career, Gary has collaborated with several talented individuals, including Peter T. Meinke and Andrew Evan Denker. These collaborations have fostered a creative environment that encourages the development of groundbreaking medical solutions.
Conclusion
Gary E. Meininger is a distinguished inventor whose work in anti-diabetic treatments has the potential to improve the lives of many individuals suffering from type II diabetes. His innovative methods and collaborations highlight the importance of research and development in the medical field.